Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Genome&Company Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.	South Korea	314130
Genomictree Inc. Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.	South Korea	228760
Genomtec S.A. Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.	Poland	GMT
GENOTECH CORP. A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.	South Korea	066830
Genprex, Inc. A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.	United States of America	GNPX
Gentian Diagnostics ASA Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.	Norway	GENT
GERON CORP Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.	United States of America	GERN
GH Research PLC Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.	United States of America	GHRS
GI Innovation Inc. Develops fusion protein biologics for oncology, allergic, and metabolic diseases.	South Korea	358570
GILEAD SCIENCES, INC. Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.	United States of America	GILD